UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE PATENT TRIAL AND APPEAL BOARD
PAR PHARMACEUTICAL, INC.  Petitioner
V.
SUMITOMO DAINIPPON PHARMA CO., LTD.  Patent Owner
U.S. Patent No. 9,555,027
Title: Pharmaceutical Composition
Inter Partes Review Case No. <u>Unassigned</u>

### **DECLARATION OF PROFESSOR GRAHAM BUCKTON**



## TABLE OF CONTENTS

I.	Introduction				
II.	Background and Qualifications				
III.	List Of Documents Considered In Forming My Opinions				
IV.	My Understanding of the Relevant Law				
	A. B.	Claim Construction			
V.	Level	of Ordinary Skill in the Art	12		
VI.	Summary of the '027 Patent Disclosure and Alleged Invention				
	A. B.	The Specification The Claims of the '027 Patent			
VII.	Claim construction				
	A. B.	"Pregelatinized starch" "Equivalent dissolution profile across the range of lurasidone"			
VIII.	The State of the Art in 2005				
	A. B. C.	Formulation of oral preparations with good disintegration and rapid dissolution was well known in the art  Lurasidone (and formulations thereof) were known in the art  Lurasidone was known to be effective at doses from 5 to			
	D.	120 mg			
	E.	It was known that different dosage amounts of a given formulation should be proportionally scaled, should have acceptable tablet size, and should share equivalent dissolution characteristics	36		
	F.	Pregelatinized starch was a commonly used disintegrant (and multifunctional excipient) in oral dosage forms			
	G.	Pregelatinized starch was known to impart rapid dissolution and disintegration behavior in immediate release oral dosage forms	44		



	H.	Pregelatinized starch was used in formulations of poorly	10		
	I.	soluble APIs to impart rapid dissolution and disintegration	46		
	1.	The beneficial dissolution and disintegration behavior of pregelatinized starch was known to apply to formulations with a			
		wide range of API loading	48		
	J.	Pregelatinized starch was typically used in amounts ranging	40		
	J.	from 1-75% of total weight of the oral dosage form	49		
		from 1-75% of total weight of the ofal dosage form	·Ŧノ		
IX.	Summary of Prior Art				
	A.	EP 1 327 440 A1 (Ex. 1008, "Fujihara")	50		
	В.	PHARMACEUTICS: THE SCIENCE OF DOSAGE FORM DESIGN			
	٥.	(Michael E. Aulton ed., 1988) (Ex. 1009, "Aulton")	58		
	C.	U.S. Patent No. 4,911,921 (Ex. 1010, "Denton")			
	D.	Chowdary, K.P.R. and Rama Rao, N., "Formulation and	02		
	Σ.	Evaluation of Dispersible Tablets with Pregelatinized Starch,"			
		Indian Drugs, 35(6):368-371 (1998) (Ex. 1011, "Chowdary")	64		
		mann Drugs, 55(0).500 571 (1990) (Ex. 1011, "Chowdary")	0 1		
X.	Sumitomo did not fairly Characterize the prior art during prosecution				
	A.	The prior art does not support Sumitomo's argument that			
		pregelatinized starch has unpredictable effects on dissolution	67		
	B.	Salpekar does not teach away from the claimed range of			
	_,	pregelatinized starch	72		
	C.	One of ordinary skill would consider formulations of other			
	٠.	poorly soluble APIs relevant to formulations of lurasidone	77		
		poorly solution in its fellowant to formulations of furusitione in	,		
XI.	Over	view of my conclusions	79		
XII.	The Challenged Claims would have been Obvious to One of Ordinary				
	Skill in 2005				
	A.	The Challenged Claims were obvious over Fujihara in view of			
	л.	Aulton	<b>Q</b> 1		
		Fujihara discloses ranges of lurasidone content and	01		
		excipients that overlap with the Challenged Claims	82		
		2. One of ordinary skill would have been motivated to	0∠		
		increase the dose of lurasidone in Fujihara while			
		maintaining equivalent dissolution between doses	Q A		
		<del>y</del> •	04		
		3. One of ordinary skill would have used the higher content of lurasidone disclosed in Fujihara	86		
		OF INFANIOUS UINCIOSEU III PIHIMATA	AD		



		4. One of ordinary skill was motivated to select a known	
		disintegrant in Fujihara	87
		5. It would have been obvious to combine Fujihara with	
		Aulton to select pregelatinized starch as a disintegrant	
		because pregelatinized starch was in a small group of	
		commonly used disintegrants	88
		6. There is no evidence of unexpected results of the claimed	
		ranges	93
		7. Combining Fujihara with Aulton yields every limitation	
		of the challenged claims	100
	B.	The Challenged Claims would have been obvious over Fujihara	
		in view of Denton and Chowdary	118
		1. One of ordinary skill would have been motivated to	
		improve the oral preparations of Fujihara to increase the	
		dose of lurasidone while maintaining equivalent	
		dissolution between doses	118
		2. One of ordinary skill would have used the higher content	
		of lurasidone disclosed in Fujihara	119
		3. To limit tablet size and maintain equivalent dissolution	
		profiles between doses across a broad range, one of	
		ordinary skill would have looked to Denton's use of	
		pregelatinized starch	119
		4. One of ordinary skill further would have looked to	
		Chowdary to use 10%-20% pregelatinized starch	123
		5. There is no evidence of unexpected results for the	
		claimed ranges.	126
		6. Combining Fujihara with Denton and Chowdary yields	
		every limitation of the Challenged Claims	127
	C.	Reasonable Expectation of Success	
		•	
XIII.	There	e Are No Secondary Considerations of Non-Obviousness	136
XIV.	Conc	lusion	137



I, Professor Graham Buckton, hereby declare as follows.

#### I. INTRODUCTION

- 1. I am over the age of eighteen and otherwise competent to make this declaration.
- 2. I have been retained as an expert witness on behalf of Par Pharmaceutical, Inc. ("Par") for the above captioned *inter partes* review ("IPR"). I am being compensated for my time in connection with this IPR at my standard consulting rate, which is £375 per hour for my work on this matter. I also am reimbursed for travel and other direct expenses. I have no personal or financial interest in the outcome of this proceeding.
- 3. I understand that this declaration is being submitted in support of a petition for IPR of U.S. Patent No. 9,555,027 (Ex. 1001, "the '027 Patent"), which issued from U.S. Application No. 14/512,189 ("the '189 application") on January 31, 2017. The '027 Patent names Kazuyuki Fujihara as inventor. I further understand that, according to USPTO records, the '027 Patent is currently assigned to Sumitomo Dainippon Pharma Co., Ltd. ("Patent Owner").
- 4. The cover page of the '027 Patent indicates that it was filed as the '189 application on October 10, 2014. The cover page of the '027 Patent also claims priority to two related U.S. patent applications, U.S. Non-provisional Application No. 14/183,283 ("the '283 application," filed on February 18, 2014),



# DOCKET

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

# **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

### **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

#### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

#### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

